Preferred Label : mepolizumab;

MeSH note : a humanized monoclonal antibody to IL-5 in cynomolgus monkeys;

CISMeF synonym : SB-240563;

MeSH hyponym : SB240563;

Is substance : O;

UNII : 90Z2UF0E52;

Details


Main resources

You can consult :


https://www.has-sante.fr/jcms/p_3539147/fr/nucala-mepolizumab-biotherapies-par-voie-sous-cutanee-dans-les-maladies-inflammatoires-chroniques
2024
false
false
false
France
drug prescriptions
evaluation of the transparency committee
biological therapy
mepolizumab
chronic disease
injections, subcutaneous

---
https://www.has-sante.fr/jcms/p_3473151/fr/fiche-bum-dupixent-fasenra-nucala-tezspire-et-xolair-dans-le-traitement-de-l-asthme-severe
2024
false
false
false
France
dupilumab
benralizumab
mepolizumab
tezepelumab
other systemic drugs for obstructive airway diseases
adult
child
drug therapy, combination
Severe persistent asthma (disorder)
adolescent
Respiratory corticosteroid (substance)
adrenergic beta-2 receptor agonists
guidelines for drug use
Omalizumab
asthma

---
https://www.rheuma-net.ch/fr/doc/mepolizumab/viewdocument/572
2024
Switzerland
guideline
mepolizumab
mepolizumab
Mepolizumab
Background Treatment

---
https://www.has-sante.fr/jcms/p_3339054/fr/nucala-mepolizumab-granulomatose-eosinophilique-avec-polyangeite
2022
false
false
false
France
insurance, health, reimbursement
treatment outcome
child
adolescent
recurrence
drug resistance
injections, subcutaneous
churg-strauss syndrome
Eosinophilic Granulomatosis with Polyangiitis
evaluation of the transparency committee
mepolizumab

---
https://www.cadth.ca/fr/mepolizumab-2
2022
false
false
false
Canada
French
English
nasal polyps
mepolizumab
Chronic rhinosinusitis with nasal polyps
drug evaluation

---
https://www.has-sante.fr/jcms/p_3341449/fr/nucala-mepolizumab-syndrome-hypereosinophilique
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
injections, subcutaneous
idiopathic hypereosinophilic syndrome
adult
Lymphocytic hypereosinophilic syndrome
evaluation of the transparency committee
hypereosinophilic syndrome
mepolizumab

---
https://www.has-sante.fr/jcms/p_3358115/fr/nucala-mepolizumab-asthme-severe-refractaire-a-eosinophiles
2022
false
false
false
France
treatment outcome
insurance, health, reimbursement
Eosinophilic asthma
adult
mepolizumab
evaluation of the transparency committee
mepolizumab
asthma

---
https://www.has-sante.fr/jcms/p_3380395/fr/nucala-mepolizumab-asthme-severe-a-eosinophiles-pour-les-enfants-de-6-ans-et-plus-et-les-adolescents
2022
France
evaluation of the transparency committee
mepolizumab
child, nos
mepolizumab
adolescence
severe
eosinophils
Asthma
Adolescent
asthma
Adolescent
child
Nucala
asthma
Child
Child
pulmonary eosinophilia
Eosinophilia
Child
eosinophilia
adolescent
Child

---
https://www.has-sante.fr/jcms/p_3349481/fr/nucala-mepolizumab-polypose-naso-sinusienne
2022
false
false
false
France
French
evaluation of the transparency committee
treatment outcome
insurance, health, reimbursement
mepolizumab
injections, subcutaneous
mepolizumab
Nasal polyposis
nasal polyps
adult

---
https://www.has-sante.fr/jcms/p_3191484/fr/nucala
2020
false
false
false
France
mepolizumab
insurance, health, reimbursement
adult
adolescent
child
asthma
eosinophilia
Eosinophilic asthma
injections, subcutaneous
evaluation of the transparency committee
mepolizumab
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/c_2804050/fr/fasenra-benralizumab-et-nucala-mepolizumab-dans-le-traitement-de-l-asthme-severe
2019
false
false
false
France
French
asthma
eosinophilia
benralizumab
benralizumab
mepolizumab
health technology assessment
mepolizumab
Eosinophilic asthma
adult
adolescent
child
drug therapy, combination
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3083091/fr/nucala
2019
false
false
false
France
mepolizumab
asthma
eosinophilia
Eosinophilic asthma
child
adolescent
injections, subcutaneous
treatment outcome
insurance, health, reimbursement
mepolizumab
antibodies, monoclonal, humanized

---
https://www.has-sante.fr/jcms/p_3121604/fr/nucala
2019
false
false
false
France
mepolizumab
asthma
eosinophilia
Eosinophilic asthma
adult
adolescent
child
injections, subcutaneous
evaluation of the transparency committee
mepolizumab
antibodies, monoclonal, humanized

---
http://www.cochrane.org/fr/CD010834/les-therapies-anti-il5-pour-le-traitement-de-lasthme
2017
false
false
false
false
France
United Kingdom
French
review of literature
adult
child
asthma
mepolizumab
mepolizumab
french abstract
mepolizumab
antibodies, monoclonal, humanized
reslizumab
benralizumab
Childhood asthma (disorder)

---
https://www.has-sante.fr/portail/jcms/c_2804050/fr/quelle-place-pour-cinqaero-et-nucala-dans-le-traitement-de-l-asthme-severe
2017
false
false
false
France
French
guidelines for drug use
reslizumab
reslizumab
reslizumab
infusions, intravenous
adult
drug therapy, combination
mepolizumab
mepolizumab
mepolizumab
injections, subcutaneous
Eosinophilic asthma
asthma
eosinophilia
Severe asthma (disorder)
adrenergic beta-2 receptor agonists
glucocorticoids
algorithms
treatment outcome
Interleukin-5
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Progrès thérapeutique mineur dans la prise en charge de l’asthme sévère réfractaire à éosinophiles
http://www.has-sante.fr/portail/jcms/c_2655935/fr/nucala
http://www.has-sante.fr/portail/jcms/c_2655935/fr/nucala-mepolizumab-anticorps-monoclonal-anti-il5
2016
false
false
false
false
France
French
mepolizumab
adult
asthma
Eosinophilic asthma
eosinophilia
Interleukin-5
injections, subcutaneous
treatment outcome
mepolizumab
evaluation of the transparency committee
insurance, health, reimbursement
guidelines for drug use
mepolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Summary Basis of Decision - Nucala - Health Canada
Mepolizumab, 144 mg/vial (100 mg/mL, powder for solution, subcutaneous
https://hpr-rps.hres.ca/reg-content/summary-basis-decision-detailTwo.php?lang=en&linkID=SBD00279
2016
false
false
false
false
Canada
French
English
summary of product characteristics
mepolizumab
mepolizumab
risk assessment
adult
asthma
Eosinophilic asthma
eosinophilia
Interleukin-5
injections, subcutaneous
treatment outcome
product surveillance, postmarketing
clinical trials as topic
mepolizumab
drug approval
canada
mepolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
http://www.revmed.ch/RMS/2015/RMS-N-456-457/Pneumologie-BPCO-asthme-et-fibrose-pulmonaire
2015
false
false
false
Switzerland
French
journal article
pulmonary disease, chronic obstructive
adrenal cortex hormones
adrenal cortex hormones
Eosinophilic asthma
asthma
Severe asthma (disorder)
treatment outcome
mepolizumab
asthma
idiopathic pulmonary fibrosis
Adrenocortical steroid therapy
corticosteroid therapy
antibodies, monoclonal, humanized

---
https://www.ema.europa.eu/medicines/human/EPAR/Nucala
2015
false
false
false
United Kingdom
French
English
treatment outcome
syndication feed
summary of product characteristics
package leaflet
drug evaluation
drug approval
europe
mepolizumab
mepolizumab
asthma
drug interactions
pregnancy
breast feeding
drug evaluation, preclinical
drug therapy, combination
Eosinophilic asthma
Severe asthma (disorder)
injections, subcutaneous
Interleukin-5
product surveillance, postmarketing
mepolizumab
antibodies, monoclonal, humanized
antibodies, monoclonal, humanized

---
Nous contacter.
03/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.